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ABSTRACT: The COVID-19 pandemic has had a devastating global impact, with older adults being most at risk 
of death from the disease. However, acute sarcopenia occurs in survivors of COVID-19; older adults and the most 
critically unwell patients are the most at risk. Acute sarcopenia is an under-recognised condition of acute muscle 
insufficiency, defined by declines in muscle function and/or quantity within six months, usually following a 
stressor event. This commentary reviews definition and mechanisms of acute sarcopenia in COVID-19 and 
suggests recommendations for research and clinical practice. Research should now focus on the longer-term 
consequences of acute sarcopenia in patients who have suffered from COVID-19. At the same time, clinicians 
need to be increasingly aware of the condition, and measurements of muscle strength, quantity, and physical 
performance should be embedded into clinical practice. Clinicians should consider the risks of acute sarcopenia 
when weighing up the risks and benefits of treatment (e.g. dexamethasone), and instigate multidisciplinary 
treatment including dietetics input.  
 







Sarcopenia is a condition of extreme muscle insufficiency 
[1], defined by reduced muscle strength with reduced 
muscle quantity and/or muscle quality [2]. Severe 
sarcopenia is defined by additional demonstration of low 
physical performance. Cut-offs are taken as more than two 
standard deviations below the mean of a young healthy 
reference population [2]. Sarcopenia is associated with 
limitations upon physical function and quality of life [3], 
increased risk of falls [4], and increased mortality [5]. It 
has been considered a precursor or physical manifestation 
of frailty, a state of increased vulnerability [6]. Acute 
sarcopenia is defined by the European Working Group on 
Sarcopenia in Older People 2 (EWGSOP2) as incident 
sarcopenia within six months, normally following a 
stressor event [2]. Acute sarcopenia most commonly 
occurs in hospitalised patients. Older adults with frailty 
are considered to be most vulnerable [7], however, it is 
increasingly recognised that sarcopenia can develop at 
any age [8]. Previously robust individuals may develop 
acute sarcopenia following severe illness and admission 
to critical care [7]. Acute sarcopenia is akin to acute organ 
insufficiency elsewhere e.g. Acute Kidney Injury [7].  
Sarcopenia is common in hospitalised populations [9-
12] and associated with increased risk of adverse 
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outcomes; low muscle quantity has been associated with 
increased risk of post-operative infections and mortality , 
as well as increased rehabilitation needs and length of stay 
in surgical populations [13-16]. Sarcopenia has been 
associated with reduced diaphragmatic muscle thickness 
[17]. Acute declines in diaphragmatic muscle thickness in 
hospitalised patients can provoke respiratory failure, and 
necessitate prolonged mechanical ventilation in critically 
unwell patients [18]. Although the current definition of 
sarcopenia refers to an extreme level of muscle 
insufficiency, it is also recognised that relative changes 
for individuals that do not meet the criteria for sarcopenia 
may be themselves individually significant [7]. The 
longer-term effects of acute sarcopenia remain unknown 
[7]. However, acute sarcopenia will lead to significant 
detriments in physical function, at least in the short-term, 
and it has been hypothesised that periods of acute 
sarcopenia may increase the risk of developing chronic 
sarcopenia [7].  
Muscle loss in acute sarcopenia is due to an 
imbalance in muscle homeostasis with increased muscle 
degradation and reduced muscle synthesis.  Muscle 
degradation is a term which broadly describes the loss of 
muscle via both reduction in muscle fibre size (atrophy) 
and reduction in the number of muscle fibres (hypoplasia). 
Hypoplasia is believed to occur secondary to motor 
neurone death and muscle fibre denervation and atrophy 
secondary to proteolytic pathways [19]. Older adults 
exhibit a blunted synthetic response to both feeding and 
exercise, termed anabolic resistance, compared to young 
adults [20-22].  However, in acute illness catabolic 
pathways are likely to be more relevant. 
Unfortunately, measurement of muscle strength or 
muscle quantity are not currently fully integrated into 
routine clinical care, although anthropometry may be 
performed as part of a dietetics assessment [23]. 
Therefore, acute sarcopenia is an often-unconsidered 
organ insufficiency, as it requires a comprehensive 
evaluation of the patient to be identified; it cannot be 
identified through remote review of biochemistry or vital 
signs alone. Without consideration of dynamic changes in 
muscle strength and quantity, acute sarcopenia may go 
unnoticed until it is clinically extreme. The importance of 
muscle insufficiency may be disregarded by clinicians 
when the initial focus of care is on survival. However, it 
is always important to consider the wishes of the patient 
themselves, since for many, survival with good physical 
function may be just as important, if not more important 
than survival itself [24]. Additionally, deprioritising the 
muscle within early clinical care risks further challenges 
as rehabilitation is likely to be prolonged and more 
difficult [25], leading to increased lengths of stay, and 
increased vulnerability to further illnesses, and  a negative 




Figure 1. Mechanisms of acute sarcopenia development with COVID-19.  Precipitating factors for acute sarcopenia with COVID-
19 are demonstrated by pathways and predisposing factors are shown separately. MPB = Muscle Protein Breakdown; MPS = Muscle 
Protein Synthesis 
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Mechanisms of acute sarcopenia with COVID-19 
 
Coronavirus disease 2019 (COVID-19) is a severe acute 
infectious disease caused by the Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) [26]. The global 
pandemic caused by this virus has resulted in 
unprecedented global healthcare demand. The initial 
focus of care within the pandemic was to prevent 
unnecessary deaths from the infection [27]; older adults 
are known to be particularly vulnerable to the effects of 
the illness, with age associated with increased mortality 
[28]. However, it has now become clear that survivors of 
COVID-19 are at increased risk of acute sarcopenia [29, 
30], with worsening muscle insufficiency identified 
across a multitude of settings [31, 32].  Figure 1 
demonstrates proposed mechanisms of acute sarcopenia 
with COVID-19 as described below.  
Inflammation 
COVID-19 is known to be associated with significant 
systemic inflammation and a subset of patients will 
experience a severe cytokine response. Serum 
concentrations of inflammatory cytokines including 
Tumour Necrosis Factor Alpha (TNF-α) have been shown 
to be higher in patients with COVID-19 requiring critical 
care treatment [33]. This has negative consequences upon 
muscle protein synthesis; TNF-α decreases messenger 
Ribonucleic Acid (mRNA) translational efficiency 
through alterations in Eukaryotic translation initiation 
factor 4E (eIF-4E) availability [34]. This results in a state 
of anabolic resistance, which necessitates a requirement 
for higher protein intake to stimulate muscle protein 
synthesis. Rodent models of sepsis have also shown 
increases in the muscle-specific ubiquitin ligases (Muscle 
Ring Finger 1, MuRF-1 and Muscle Atrophy F-box, 
MAFbx) in relation to inflammation [35]. Ageing itself is 
associated with increased cellular senescence. Although 
senescent cells represent a state of arrested cell growth, 
they also secrete high levels of inflammatory cytokines 
[36]. Thus, the effects of inflammation and acute illness 
may be exacerbated with age.  
Vitamin D 
Vitamin D deficiency has been implicated in sarcopenia; 
muscle biopsies from individuals with vitamin D 
deficiency have shown atrophy of Type II muscle fibres 
[37]. Vitamin D has also been hypothesised to affect the 
immune response to respiratory infections [38]. However, 
vitamin D deficiency is increasingly recognised to occur 
as a consequence of inflammation rather than a cause [39]. 
Thus, vitamin D deficiency in critical illness may simply 
represent a biomarker of heightened inflammation. Some 
studies have demonstrated an association between low 
vitamin D and development of COVID-19 [40, 41], but no 
causal relationship has been demonstrated after adjusting 
for multiple confounders [40].  
Obesity 
Obesity has been demonstrated as an adverse prognostic 
factor in COVID-19, being associated with increased risk 
of hospitalisation, critical care admission, and mortality 
[42]. Obesity in itself is associated with increased 
systemic inflammation, which may exacerbate the effects 
of acute illness upon muscle metabolism. Sarcopenic 
obesity is a recognised condition defined by reduced 
muscle mass with increased fat mass. Sarcopenic obesity 
may also be associated with ectopic deposition of fat and 
intramyocellular lipid deposition, thus affecting the 
quality of muscle [43]. This effect may have predisposed 
individuals with obesity and catabolic states from their 
illness to significant declines in muscle function in 
association with declines in muscle quantity.  
Critical care admission 
The most marked individual declines in muscle function 
in hospitalised patients with COVID-19 were seen in 
patients who required admission to critical care [31], 
relating to marked elevations in systemic inflammation, 
prolonged bedrest, and use of muscle relaxants to aid 
prone positioning and reduce risk of viral spread [44]. 
Acute sarcopenia has been demonstrated in patients who 
were previously fit and active prior to hospital admission, 
but experienced severe declines in their muscle function. 
In many patients, this also led to a state of induced frailty 
[45], with  increased vulnerability to  stressor events [46]. 
Induced frailty in itself led to further compromises to the 
immune system, making the patients more vulnerable 
during their recovery [45].  
Nutrition 
As described, research suggests that heightened 
inflammation in COVID-19 is associated with catabolic 
states and anabolic resistance, leading to increased 
nutritional demand, particularly protein. Despite this, 
many patients with COVID-19 struggled to meet even 
basic requirements. Loss of sense of taste or smell  are 
recognised symptoms of COVID-19, that may occur in up 
to two thirds of cases [47]. This leads to diminished 
appetite. In addition, upregulation of proinflammatory 
cytokines, as seen in COVID-19, is associated with 
induction of leptin and anorexia [48]. Combined with the 
effects of anorexia of ageing [49], older adults may be 
particularly vulnerable to these effects. In addition, 
sarcopenia in itself has been shown to be associated with 
weakness in masticatory muscles, which may further 
exacerbate diminished food intake [50].  
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Bedrest and physical activity 
Importantly, many patients hospitalised with COVID-19 
suffered prolonged periods of bedrest and reduced 
physical activity. Depending on hospital models, this may 
have been further exacerbated by isolation policies 
preventing mobilisation outside of smaller ward areas or 
side rooms. Even in those who did not require 
hospitalisation, there is evidence that patients who 
contracted COVID-19 suffered from immense fatigue. 
This is likely to have reduced their physical activity [29]. 
During the COVID-19 pandemic, most countries also 
placed restrictions on activities that could be conducted in 
order to combat spread of the virus. Older adults were 
considered the most vulnerable, and often had the greatest 
restrictions placed on them. This is likely to have 
significantly affected the amount of physical activity 
engagement by older adults during this time period [51], 
making them increasingly vulnerable if they did require 
hospitalisation. Bedrest has been shown to be associated 
with declines in muscle quantity, strength, and aerobic 
performance in healthy volunteer studies [52]. This effect 
is exacerbated by age [53]. Bedrest leads to reduced 
muscle protein synthesis via altered expression of 
ubiquitin ligases in healthy young adults (MuRF-1 and 
MAFbx) [54, 55]. 
COVID-19 treatment 
The effect of treatment initiated for COVID-19 should 
also be considered. The Randomised Evaluation of 
COVID-19 Therapy (RECOVERY) trial demonstrated a 
survival benefit with dexamethasone, particularly when 
given to the most unwell patients [56]. However, 
medically-induced hypercortisolaemia has been shown to 
induce muscle loss with bedrest compared to bedrest 
alone [57]. Dexamethasone itself has been shown to up-
regulate MuRF-1 and MAFbx 10-fold in rodent models 
[58]. Therefore, dexamethasone may increase risk of 
acute sarcopenia in already vulnerable patients.   
Recovery 
Previous research completed in patients with Acute 
Respiratory Distress Syndrome has demonstrated a 
decrease in lean muscle mass during the year following 
discharge from critical care [59]. This suggests a lasting 
effect preventing the synthesis of new muscle following 
acute severe illness.  Murine models of sepsis have 
demonstrated that muscle regeneration capabilities 
following sepsis are severely limited; increased fibrosis as 
well as a decreased number and function of satellite cells 
[60].  It is hypothesised that prolonged immune changes 
as a consequence of sepsis or COVID-19 result in a 
reduction in the body’s ability to synthesise muscle with 
protracted sequalae of acute sarcopenia.        
Recommendations for research and clinical practice 
 
Research that aims to characterise changes in muscle 
quantity, quality, and function in hospitalised patients 
with COVID-19 and other conditions [61] is imperative 
towards increasing our understanding of this condition. 
Mechanistic and biomarker-driven studies will enable 
increased understanding of the underlying molecular 
pathways to guide risk stratification in patients, as well as 
assisting with development of novel treatment pathways. 
Longer term cohort studies, such as the Post-
Hospitalisation COVID-19 (PHOSP-COVID) study [62], 
which includes a sarcopenia subgroup, will enable 
detailed phenotyping of patients who have developed 
acute sarcopenia, and increased understanding of 
recovery within one year of illness. Where feasible, 
muscle biopsies may provide valuable mechanistic 
characterisation during the acute phase of illness and 
recovery; these are planned as part of the PHOSP-COVID 
study [62]. Although it is recognised that muscle biopsies 
are often less feasible in older people with frailty [63]. 
Targeted interventional studies will also enable 
identification of cost-effective strategies to prevent and 
treat acute sarcopenia in further patients who are 
hospitalised as the pandemic continues, with the potential 
for use in other illnesses.  
At the same time, clinicians need to be increasingly 
aware of the problem of acute sarcopenia. Where possible, 
clinicians should integrate serial measurements of muscle 
strength, physical performance, and muscle quantity into 
their clinical practice, enabling them to identify early 
when there is a change, and assess responsiveness to 
treatment and therapy. Without any form of monitoring, 
acute sarcopenia will not be identified until clinically 
extreme. Muscle strength can be measured using a 
dynamometer, where available; assessment of chair 
stands is an alternative where a dynamometer is not 
available and the patient is able to sit in a chair [2]. 
Ultrasound and bioelectrical impedance analysis are 
options for measurement of muscle quantity [2], and even 
anthropometry (e.g. calf size) [64] can be of value in a 
time-limited environment, when no other methods are 
available. Importantly, these methods can be implemented 
even when it is not possible to assess muscle function (e.g. 
intubated patients in critical care). In awake patients, the 
Hierarchical Assessment of Balance and Mobility 
(HABAM) is an instrument that provides dynamic 
assessment of in-bed balance, transfers, and ambulation 
[65]; integrating this into clinical practice can allow 
monitoring of in-hospital function in the same way as vital 
signs.  
In any care model for patients suffering from or 
recovering from COVID-19, treatment needs to enlist a 
multidisciplinary approach [25]. Early dietetics 
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involvement is paramount to optimise protein intake 
particularly. In some cases, up to 2g protein/kg/day may 
be required [66], and this may even necessitate a period of 
nasogastric feeding [67]. An enhanced physiotherapy 
programme should focus on graded response, assessing 
what is feasible within the clinical environment. Whilst 
infection control policies will necessitate isolation from 
patients without COVID-19, clinical areas should enable 
mobilisation as much as possible e.g. by cohorting 
patients with COVID-19 together.  Specialised wards with 
strength training equipment will help to build a supportive 
environment focused around rehabilitation. However, 
ideally a rehabilitation ethos and therapy provision should 
be embedded throughout the hospital, to enable treatment 
to commence even in the early acute phase. Clinicians 
should carefully consider the risks and benefits of all 
treatment. Dexamethasone is now given routinely to 
hospitalised patients with COVID-19 requiring oxygen or 
critical care admission. However, clinicians should be 
aware of the potential for increased risk of muscle loss if 
prolonged courses are given. The longer-term 
consequences of COVID-19 and acute sarcopenia are 
unknown. We recommend incorporation of muscle 
function evaluation in services providing clinical follow-
up to enable referral to rehabilitation, dietetics, and other 




Acute sarcopenia is a condition of severe acute muscle 
insufficiency that normally occurs following a stressor 
event; COVID-19 is a particularly aggressive insult. 
Further research is needed to help characterise this 
condition and understand the longer-term consequences. 
This will enable the development of targeted 
interventions. Meanwhile, clinicians should be aware of 
this condition within their own practice and seek early 
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